Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308282 | 0.88 | TSHR (0.48) | TSHRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL104349 | 0.85 | — | — | |
| Hydrogen Sulfide SCHEMBL27475001 | 0.83 | TSHR (0.48) | TAAR1TSHRHTR2AMEN1KMT2A | |
| SCHEMBL27556453 | 0.83 | TSHR (0.48) | TAAR1TSHRHTR2AMEN1KMT2A | |
| SCHEMBL309287 | 0.81 | MKNK1 (0.45) | TSHRMEN1KMT2ACA1CA2 | |
| SCHEMBL13599813 | 0.81 | MKNK1 (0.45) | TSHRMEN1KMT2ACA1CA2 | |
| SCHEMBL22941869 | 0.81 | MKNK1 (0.45) | TSHRMEN1KMT2ACA1CA2 | |
| SCHEMBL9891695 | 0.81 | TSHR (0.48) | TSHRALDH1A1HPGDMEN1KMT2A | |
| Ethylene SCHEMBL27826005 | 0.80 | TSHR (0.46) | TAAR1TSHRHTR2AIDO1CYP2A6 | |
| SCHEMBL23714869 | 0.80 | CYP2A6 (0.57) | TAAR1TSHRHTR2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108610471-B | Photocrosslinkable hole transport polymer and preparation method and application thereof | 华南理工大学 | 2020-04-28 | — | — | CN | disclosed |
| CN-108610471-A | A kind of hole transport polymer of Photocrosslinkable and the preparation method and application thereof | 华南理工大学 | 2018-10-02 | — | — | CN | disclosed |
| US-9944593-B2 | Process for the synthesis of fluoralkyl sulfonate salts | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20160237028-A1 | PROCESS FOR THE SYNTHESIS OF FLUORALKYL SULFONATE SALTS | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| EP-3052474-A1 | PROCESS FOR THE SYNTHESIS OF FLUORALKYL SULFONATE SALTS | Solvay Specialty Polymers Italy S.p.A. (IT) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049239-A1 | PROCESS FOR THE SYNTHESIS OF FLUORALKYL SULFONATE SALTS | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237028-A1 | PROCESS FOR THE SYNTHESIS OF FLUORALKYL SULFONATE SALTS | PFAS, SRM, GMPS | TAAR1 1641/4885TSHR 673/4885HTR2A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.